Iranian Journal of Immunology

Immunologic Basis and Immunoprophy-laxis of RhD Induced Hemolytic Disease of the Newborn (HDN)

Document Type : Review Article

Authors

Roya Payam Khaja Pasha 1
Fazel Shokri 2, 3

1 StemCore Laboratories, Sprott Centre for Stem Cell Research, Ottawa Health Research Institute, Ottawa, Canada

2 Department of Immunology, School of Public Health, Tehran University of Medical Sciences

3 National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

https://doi.org/10.22034/iji.2008.17167
Abstract
RhD antigen is the most immunogenic and clinically significant antigen of red blood cells after ABO system. It has historically been associated with hemolytic disease of the newborn (HDN) which is now routinely prevented by the administration of polyclonal anti-D immunoglobulin. This management of HDN has proven to be one of the most successful cases of prophylactic treatment based on antibody mediated immune sup-pression (AMIS). Despite the increasing efficiency of treatment, the mechanism of ac-tion of anti-D is not completely defined. There is a widespread interest in obtaining a reliable therapeutic monoclonal anti-D, due to difficulty of maintaining a pool of high titer volunteer donors for plasma collection and also increasing demand for antenatal prophylaxis and safety issues with plasma derived products. Candidate monoclonal anti-D preparations should demonstrate appropriate functionality in both in vitro and in vivo assays comparable to polyclonal anti-D immunoglobulin. These criteria are reviewed in addition to the factors regulating development of D specific immune response in D negative individuals and its suppression in HDN prophylaxis.

Keywords

Anti-D immunoglobulin
D antigen
Hemolytic Disease of the Newborn (HDN)
Monoclonal anti-D
Rh Blood Group System
Iranian Journal of Immunology
Volume 5, Issue 4
Autumn 2008
Pages 189-200

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us